drugset / Trial / NCT06804603

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603

Phase 2 Completed 124 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

Timeline

Start
2025-02-25
Primary completion
2025-10-06
Completion
2025-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule Oral

Indications